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Abstract
Background In recent years, the number of prescriptions
for sedative drugs has increased significantly, as has their
long-term use. Moreover, sedative use is frequently initi-
ated during hospital stays.
Objectives This study aimed to describe new prescriptions
of sedative drugs during hospital stays and evaluate their
maintenance as discharge medication.
Methods This observational prospective study took place
in an internal medicine ward of a Swiss hospital over a
period of 3 months in 2014. Demographic (age, sex,
diagnosis, comorbidities) and medication data [long-term
use of sedative drugs, new regular or pro re nata (‘as
needed’) prescriptions of sedative drugs, drug-related
problems] were collected. Sedative medications included:
benzodiazepines, Z-drugs, antihistamines, antidepressants,
neuroleptics, herbal drugs, and clomethiazole. McNemar’s
test was used for comparison.
Results Of 290 patients included, 212 (73%) were over
65 years old and 169 (58%) were women; 34% (n = 98)
were using sedative drugs long term before their hospital
stay, and 44% (n = 128) had a prescription for sedative
drugs at discharge—a 10% increase (p\ 0.05). Sedative
drugs were newly prescribed to 37% (n = 108) of patients
during their stay. Among these, 37% (n = 40) received a
repeat prescription at discharge. Over half of the sedative
drugs were prescribed within 24 h of admission. Drug-re-
lated problems were detected in 76% of new prescriptions,
of which 90% were drug–drug interactions.
Conclusion This study showed that hospital stays increased
the proportion of patients who were prescribed a sedative
drug at discharge by 10% (absolute increase). These pre-
scriptionsmay generate long-term use and expose patients to
drug-related problems. Promoting alternative approaches for
managing insomnia are recommended.
Key Points
Hospital stays increased the proportion of patients
being prescribed a sedative drug by 10% by hospital
discharge, thus potentially increasing the risk of
long-term use.
Around half (52%) of new sedative drug
prescriptions were written within 24 h of hospital
admission.
Sedative prescriptions during hospital stays expose
patients to drug-related problems.
1 Introduction
Between 20 and 50% of the world’s population experience
sleep disorders, making them a major health problem
[1, 2]. In USA, between 1993 and 2007, the number of
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prescriptions for sedative medications increased signifi-
cantly (two-fold for benzodiazepines and 30-fold for non-
benzodiazepine sedative drugs), even faster than the
number of medical consultations for sleep disorders (in-
somnia diagnoses increased up to seven-fold) [3].
In 2012, the Continuous Rolling Survey on Addictive
Behaviors and Related Risks estimated that more than
220,000 people in Switzerland were using sedative drugs
(i.e., 3% of inhabitants). Use was common in the geriatric
population, and the number of prescriptions per person
increased with age. In people over 70 years old, 11% of
men and 21.5% of women were taking sedative drugs, with
5.3% of men and 9.1% of women having used sedative
drugs almost daily for over 1 year [4].
Public health campaigns on this issue are conducted
regularly. For instance, in 2013, the Swiss canton of Vaud
conducted a regional prevention campaign entitled,
‘‘Sedatives? Not necessarily needed’’, which aimed to raise
awareness among the population and physicians about the
risks associated with sedative drug use [5].
Several adverse effects have been described for sedative
drugs, such as drowsiness, delirium, nightmares, dizziness,
falls, road traffic accidents, and depression, especially in
elderly populations [6–9]. The elderly present a higher risk
of developing severe side effects because their bodies
eliminate drugs more slowly and are more sensitive to their
effects. The elderly thus face increased risks of delirium,
cognitive impairment, or falls [8, 10]. Moreover, long-term
use of sedative drugs can decrease cognitive performance
and generate problems of tolerance and dependence [7, 8].
Overall, using sedative drugs is associated with an
increased risk of total mortality [11, 12], and thus their
long-term prescription is not recommended [7]. Product
monographs and guidelines advise short-term use and
constant reassessment of prescribed sedative drugs [7, 13].
Sleep disorders are commonly observed during hospital
stays because of patients’ particular conditions, such as
illness, pain, anxiety, an unusual living environment, or
external night-time stimuli such as noises and lights
[6, 14, 15]. Furthermore, many drugs can disrupt sleep, for
example, antidepressants, beta-blockers, bronchodilators,
corticosteroids, and neurological and psychotropic drugs
[15, 16].
One study of Australia’s general adult population
described the prevalence, consequences, and treatment of
insomnia. The prevalence of insomnia was 13–33% and the
study referred to regular difficulties in either getting to or
staying asleep [17]. Other studies reported a similar
prevalence in the general population [18–20]. Moreover,
studies conducted in hospitals have estimated the preva-
lence of benzodiazepine use at 20–45% [21–23].
Sedative drugs are frequently first prescribed during a
hospital stay and, among them, the prescription of
benzodiazepines is commonplace [24, 25]. Ideally, these
drugs should be withdrawn before patients are discharged,
however, few data are available on the proportion of
sedative drugs initiated in hospital settings and still found
on patients’ discharge prescriptions. The Swiss Society of
General Internal Medicine recently identified five priority
actions to promote smarter medicine, among which was
limiting the use of benzodiazepines or other sedative drugs
in older adults during hospital stays [26]. Similarly, in its
Choosing Wisely campaign, the American Geriatric Soci-
ety recommends not using benzodiazepines as first-line
treatment for insomnia in older adults [27, 28]. To the best
of our knowledge, only a few studies have suggested that
hospitals have an influence on the ambulatory use of
sedative drugs [29, 25, 30, 31]. One French study showed
that hospitals could have a significant impact on ambula-
tory sedative drug use, showing that 65% of sedative drugs
prescribed during a hospital stay were still prescribed at
discharge [30]. Another study showed that 43% of patients
used sedative drugs during their hospital stay, and that 33%
were still prescribed them at discharge [31]. Furthermore,
patients, especially elderly individuals, are susceptible to
drug-related problems (DRPs) linked to their ongoing
medical treatment, such as potentially inappropriate pre-
scriptions, incorrect dosages, contraindications, suboptimal
treatment duration, duplicate therapy, drug–drug interac-
tions, or other side effects. One study described how 95%
of elderly patients presented with at least one DRP as a
result of their treatment [32]. With regard to sedative drugs,
another study showed that 77% of new benzodiazepine
prescriptions during hospital stays were considered to be
potentially inappropriate prescriptions [33]. Moreover, the
use of benzodiazepines is considered as inappropriate in
the STOPP/START tool for detecting potentially inappro-
priate prescriptions in the elderly [34]. The present study
aimed to describe the prescription of new sedative drugs
during hospital stays in an internal medicine ward and
evaluate their maintenance as discharge medication.
2 Methods
2.1 Setting and Participants
The present study was descriptive, observational,
prospective, and monocentric. It took place in the 70-bed
internal medicine ward of a Swiss hospital (Hoˆpital Riv-
iera-Chablais, Vaud-Valais). Patients were enrolled during
the 3-month period from May to August 2014.
Every day, a clinical pharmacist identified potential
participants via the hospital’s administrative software
(Opale, Version 6.8; Ordi-conseil SA, Lausanne,
Switzerland). Patients admitted to the internal medicine
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ward were screened using the study inclusion criteria (aged
18 years or more, a hospital stay of more than 24 h, the
capacity of judgment, alive at discharge, proficiency in
French, and informed consent).
2.2 Outcomes and Variables
The term ‘sedative drugs’ referred to all drugs with seda-
tive properties administered for the treatment of sleep
disturbances (including off-label use) after 6 p.m. (the
usual evening medication administration time in our hos-
pital). This included: benzodiazepines, benzodiazepine-re-
lated drugs (Z-drugs), antihistamines, antidepressants,
neuroleptics, barbiturates and their derivatives, herbal
drugs, and other sedative drugs (clomethiazole). Although
the use of herbal drugs (such as valerian) is not evidence
based, this drug is regularly used in our hospital in the
attempt to limit the use of other sedative drugs.
The study was divided into three parts. The first part
described the long-term use of sedative drugs and focused
only on patients already taking them, whether pro re nata
(PRN, or ‘as needed’) or regularly, before their hospital stay.
These patients were identified during the eligibility assess-
ment by using a short oral questionnaire on their prior con-
sumption of sedative drugs. The questionnaire included
items about: the type of sedative used (brand name and active
ingredient), dosage, rate of use, and treatment duration for all
the sedative drugs included in the study. The second part
focused on the use of sedative drugs initiated during the
hospital stay. All eligible patients were included and fol-
lowed prospectively to identify any new sedative prescrip-
tions. Demographic data (age, sex), clinical data (diagnosis,
comorbidities), and the number of occupied beds in the room
(a hypothetical reason for a sleep disorder) were noted.
Diagnoses and comorbidities were subsequently classified
into broader categories. Medication data (long-term use of
sedative drugs, new prescriptions of sedative drugs, the
prescriber, drug class, administrative data, prescription
duration, DRPs, and the discharge prescription) were col-
lected from patients’ electronic medical records (Soarian,
Version 3.04 SP12; Siemens Medical Solutions, Malvern,
PA, USA). Information on new prescriptions of sedative
drugs (during the hospital stay and at discharge) was col-
lected from the hospital’s computerized physician order
entry system (Predimed, Version 2.12.2; Lausanne
University Hospital, Lausanne, Switzerland).
Part three focused on medication reviews to identify
potential DRPs generated by new sedative prescriptions for
patients already taking other long-term medication. Newly
initiated sedative drugs were analyzed for potential DRPs
according to the following criteria: duplicate therapy,
contraindications, side effects, drug–drug interactions, drug
dosages, or therapeutic adherence. Duplicate therapy was
defined as the use of two or more sedative drugs from the
same therapeutic class (e.g., two benzodiazepines). Over-
dosage (more than the dosage approved by Switzerland’s
official information drug regulatory agency), under-dosage
(less than the approved amount), or inadequate dosage,
according to the patient’s physiological state (e.g., renal or
hepatic insufficiency), were defined based on the recom-
mendations found in the product information [7]. If dose
data were missing or insufficient, Micromedex (Truven
Health Analytics, Ann Arbor, MI, USA) [35] and Lexi-
comp Online (Lexicomp, Hudson, OH, USA) [8] were
used. Lexi-Interact (Lexicomp, Hudson, OH, USA) [8]
was used to check drug–drug interactions. As clomethia-
zole was not listed in these databases, interactions related
to this drug were checked according to the product infor-
mation and deduced from its mechanism of action and
properties. Drug-related problems were identified with
reference to the criteria used in previous studies defining
DRPs [32, 36], as well as to the Swiss Association of
Public Health Administration and Hospital Pharmacists’
system for pharmaceutical interventions [37].
2.3 Statistical Analysis
Descriptive statistics (means, proportions, standard devia-
tions, confidence intervals, and graphic representations)
were calculated using Excel (Version 2010; Microsoft
Corp, Redmond, WA, USA). Chi-square tests for associa-
tions between variables and McNemar’s test for ‘before
and after’ comparisons were carried out using STATA
(Version 13.1; StataCorp, College Station, TX, USA), and
p values[0.05 were considered statistically significant.
2.4 Ethics Approval
This study was approved by the Human Research Ethics
Committee of the Canton Vaud (Lausanne, Switzerland;
approval ID: 112/14). Oral informed consent was obtained
from each participant included in the study.
3 Results
3.1 Study Population
Of 425 patients assessed for eligibility, the study included
290 (Fig. 1); 212 (73%) participants were aged over
65 years and 169 (58%) were women. The most common
diagnoses and comorbidities were cardiovascular (68%),
metabolic (64%), urinary (37%), rheumatic and pain
(35%), gastrointestinal (35%), and neurological (34%).
Patients’ characteristics, diagnoses, and comorbidities are
described in Table 1.
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3.2 Long-Term Use of Sedative Drugs
Of the present study’s 290 patients, 34% (n = 98) had been
taking sedative drugs long term before their hospital stays,
and 74% were at least 65 years old (41% were aged
65–84 years, 33% were older). Of the 98 patients taking
sedative drugs long term, 78% agreed to answer the
questionnaire about their long-term use (n = 76; two
patients refused, 20 could not be questioned). Of the
responders, 89% took one or two sedative medications long
term and 11% took more than two drugs. The description of
this long-term sedative medication use is presented in
Table 2.
3.3 Sedative Drugs Initiated During Hospital Stay
During their hospital stay, 62% (n = 180) of the study’s
patients were prescribed at least one sedative, including
drugs that they were already prescribed, drugs newly ini-
tiated in hospital, or both. Sedative medications were ini-
tiated during hospitalization in 37% (n = 108) of patients.
Eighty-one patients were naive to these drugs, of whom
70% of patients (n = 76) were prescribed a single sedative.
The total number of newly prescribed sedative drugs was
161. Of these, 68% were prescribed for use PRN, meaning
that patients only took their sedative drug when needed.
Over half (52%) of the sedative drugs were prescribed
within 24 h of admission, and 76% of prescriptions were
not reassessed during the stay. Roughly half of sedative
prescriptions (47%) were given by the physician in charge
of the patient. Most of the prescriptions for new sedative
medications (76%) were for patients over 65 years old.
With regard to comorbidities, univariate analyses
showed that patients with psychiatric disorders were more
likely to receive a new prescription for a sedative during
their hospital stay (p\ 0.05). Moreover, patients arriving
at the hospital and whose usual treatment involved long-
term sedative drugs were less likely to receive an additional
sedative prescription during their hospital stay (p\ 0.05).
Fig. 1 Flow chart of
participants
Table 1 Patients’ characteristics (n = 290)
Characteristics n (%)
Age (years)
\65 78 (27)
65–84 132 (45)
C85 80 (28)
Sex
Female 169 (58)
Male 121 (42)
Diagnoses and comorbidities
Cardiovascular 198 (68)
Metabolic 186 (64)
Urinary 106 (37)
Rheumatic and pain 102 (35)
Gastrointestinal 101 (35)
Central or peripheral nervous system 99 (34)
Respiratory 76 (26)
Psychiatric 67 (23)
Infectious 66 (23)
Oncological 58 (20)
Hematological 35 (12)
Thromboembolic 33 (11)
Dermatological 21 (7)
Others 17 (6)
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The number of occupied beds (range 1–4) in the patient’s
room had no influence on the prescription of sedative drugs
(p[ 0.05). The most commonly prescribed sedative drugs
were benzodiazepines (47%), however, the type of sedative
drug was influenced by age (Table 3).
3.4 Medication Review of New Sedative Drug
Prescriptions
A medication review was performed for 83% of the
patients who received a new sedative prescription (n = 90;
the medication for 18 patients could not be analyzed
because information on their treatments was missing on the
day of prescription). Sometimes, new sedative drugs were
prescribed on weekends or public holidays, and it was
impossible to retrospectively determine the exact circum-
stances of those prescriptions on the next working day.
Moreover, the computerized physician order entry system
could not easily identify all the co-medications prescribed
at that specific moment. We analyzed 117 new prescrip-
tions, of which 89 (76%) presented at least one DRP: 90%
drug–drug interactions, 17% contraindications, 11%
duplicate therapies, 7% inadequate dosage according to the
physiological state, and 1% overdose. The most commonly
identified drug–drug interactions are presented in Table 4.
3.5 Sedative Drugs at Discharge
A total of 44% (n = 128) of patients received a prescrip-
tion for sedative medication at the end of their hospital
stay—a 10% increase compared with prescriptions at
admission (34%) [p\ 0.05]. Among them, 98 had already
received a sedative medication before hospitalization and
30 had a new sedative drug prescription at the discharge. In
those patients who had been prescribed a new sedative drug
during their hospital stay, 37% (n = 40) had the same
prescribed sedative medication at discharge. Table 5
summarizes the prescription of sedative drugs during hos-
pital stays and at discharge. Table 6 presents the overall
prevalence of one or more sedative drugs prescribed during
hospital stays and at discharge. Univariate analyses
revealed that several clinical factors were associated with
an increased risk of being prescribed a sedative drug at
discharge: psychiatric disorders (p\ 0.05), oncological
diagnoses (p\ 0.05), and a regularly scheduled prescrip-
tion of sedative drugs during the hospital stay (p\ 0.05).
4 Discussion
4.1 Long-Term Use of Sedative Drugs
At hospital admission, 34% of the present study’s patients
were using sedative medications long term. In two previous
Belgian and Canadian studies (2003 and 2004, respec-
tively), 29% of patients reported taking sedative drugs at
home [17, 24]. A Danish study conducted in 2010 found
similar results (30%) [38]. These slight differences from
our results might be owing to a global increase in the
consumption of these drugs by the general population over
the last 10 years.
In our study, 74% of patients using sedative drugs long
term were aged 65 years and over, and 71% had been
taking sedative drugs for at least 1 year. Guidelines for the
prescription of sedative drugs recommend short treatment
durations, not exceeding 4 weeks if possible [1, 13].
Moreover, the elderly are more subject to the side effects of
these drugs, especially in cases of long-term use
[13, 39, 40]. As in other studies, the present study con-
firmed that the patients most likely to be long-term users of
sedative drugs were generally the older ones and that
treatment durations were usually longer than recommended
[13, 16, 29].
Table 2 Long-term use of
sedative drugs prior to hospital
stay (n = 76)
Characteristics n (%)
Frequency of administration of the most commonly used sedative drug
Every day 50 (66)
1–4 times a week 16 (21)
Less than once a week 3 (4)
Unknown 7 (9)
Duration of administration of the most commonly used sedative drug
B1 year 19 (25)
[1 year 54 (71)
Unknown 3 (4)
This table’s results refer to the 76 patients who consented to answer the questionnaire, of the 98 patients
taking sedative drugs long term
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4.2 Sedative Drugs Initiated During Hospital Stay
During hospital stay, 37% (n = 108) of patients were
newly prescribed a sedative drug. The above-mentioned
Danish study found similar results (40%) [38]. Altogether,
62% of the present study’s patients were prescribed at least
one sedative drug. In the above-mentioned Belgian study,
this proportion was 45% [24]. Again, this difference might
be owing to the general increase in the consumption of
sedative drugs over the last decade. However, both the
Danish and Canadian studies [6, 38] showed similar per-
centages (62 and 60%, respectively) of patients using
sedative drugs during their hospitalization to the present
one.
Around half (52%) of new sedative medication pre-
scriptions were recorded within 24 h of admission. One
hypothesis is that these new prescriptions are the result of
the sleep disturbances observed in hospitalized patients
trying to deal with their particular situation (illness, pain,
anxiety, and a hospital setting with noises, lights, and other
patients) [15, 14]. However, this could not be confirmed: it
was impossible for our study to know the exact indications
for newly prescribed sedative drugs. Nevertheless, what-
ever the drug’s indication, it would probably have a col-
lateral sedative effect. Very few studies have shown that
being hospitalized can actually increase sleep disorders;
one French study found that this only concerned 16% of
patients [30]. However, another study showed that 9% of
patients used newly prescribed benzodiazepine drugs dur-
ing their hospital stay [24]. On hospitalization, therefore, a
brief intervention by caregivers to explain the situation and
reassure patients about their sleeping problems might prove
useful and help to avoid the prescription of unnecessary
sedative drugs.
Table 3 Types of sedative
drugs prescribed during hospital
stay
Sedative drugs Total
(n = 161)
n (%)
Age\65 years
(n = 34)
n (%)
Age 65–84 years
(n = 91)
n (%)
Age C85 years
(n = 36)
n (%)
Benzodiazepines 76 (47) 25 (73) 36 (40) 15 (42)
Lorazepam (Temesta) 31 (19) 12 (35) 16 (18) 3 (8)
Oxazepam (Seresta) 23 (14) 8 (23) 9 (10) 6 (17)
Bromazepam (Lexotanil) 9 (6) 0 (0) 5 (6) 4 (11)
Midazolam (Dormicum) 4 (3) 0 (0) 0 (0) 0 (0)
Diazepam (Valium) 3 (2) 3 (9) 4 (4) 0 (0)
Clorazepate (Tranxilium) 2 (1) 2 (6) 0 (0) 0 (0)
Alprazolam (Xanax) 2 (1) 0 (0) 0 (0) 2 (6)
Flurazepam (Dalmadorm) 2 (1) 0 (0) 2 (2) 0 (0)
Z-drugs 17 (11) 5 (15) 11 (12) 1 (3)
Zolpidem (Stilnox) 14 (9) 4 (12) 9 (10) 10 (3)
Zopiclone (Imovane) 3 (2) 1 (3) 2 (2) 0 (0)
Other sedative drugs 51 (32) 3 (9) 34 (37) 14 (39)
Clomethiazole (Distraneurin)
Antidepressants 6 (4) 1 (3) 2 (2) 3 (8)
Trazodone (Trittico) 1 (1) 0 (0) 1 (1) 0 (0)
Mirtazapine (Remeron) 5 (3) 1 (3) 1 (1) 3 (8)
Neuroleptics 5 (3) 0 (0) 5 (6) 0 (0)
Levomepromazine (Nozinan)
Herbal drugs (Valerian) 4 (2) 0 (0) 3 (3) 1 (3)
Melatonin receptor agonists 2 (1) 0 (0) 0 (0) 2 (5)
Table 4 Drug–drug interactions with new sedative prescriptions
(n = 156)
Interactions n (%)
Pharmacodynamic 136 (87)
Addition of CNS-depressant effects 123 (90)
Addition of QTc-prolongation effects 8 (6)
Increased side effects 5 (4)
Pharmacokinetic 20 (13)
Cytochrome P450 18 (90)
Increased the new sedative drug’s effects 12 (66)
Decreased the new sedative drug’s effects 3 (17)
Increased the other drugs’ effects 3 (17)
Unknown mode of action 2 (10)
CNS central nervous system, QTc corrected QT
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Benzodiazepines were the most prescribed sedative
drugs in the present work, confirming findings from pre-
vious studies [16, 25, 31]. The second most prescribed
sedative was clomethiazole, a drug prescribed quite fre-
quently in some countries (e.g., the French-speaking part of
Switzerland), but not in others (e.g., English-speaking
countries). Detailed information on clomethiazole use is
thus often missing and no recent studies are available on its
use as a sleep disorder medication. However, this drug is an
option prescribed for the management of insomnia in
preference to benzodiazepines in elderly individuals
[41–45]. However, warnings about a risk of respiratory
depression have been made, along with the recommenda-
tion that the duration of treatment should be short [1, 7, 9].
Interestingly, the type of sedative drug prescribed chan-
ged according to patients’ ages. Thus, benzodiazepines (e.g.,
lorazepam)weremainly prescribed to younger patients (73%
of sedative drug prescriptions for patients aged under
65 years), whereas clomethiazole was the most prescribed
sedative drug for patients aged 65 years or more. This con-
firmed previous findings from a study conducted at a nearby
Swiss university hospital, which showed the high prevalence
(64%) of clomethiazole prescribed to patients aged 75 years
or more; this was followed by lorazepam (11%) [46].
Antidepressants and neuroleptics were not often prescribed
in the present study. Indeed, these medications are not rec-
ommended as first-line treatments for sleep disorders and
should be reserved for patients with specific comorbidities
(e.g., depression or psychosis) [47].
4.3 Medication Review of New Sedative Drug
Prescriptions
At least one DRP was identified in 76% of cases of newly
prescribed sedative drugs. As described above, drug–drug
interactions represented the majority of DRPs, classified as
either pharmacodynamic or pharmacokinetic [7]. The most
frequent pharmacodynamic interaction was the accumula-
tion of the effects of central nervous system depressants.
These interactions occurred when sedative drugs were
concomitantly prescribed with other drugs with central
nervous system-depressant properties, such as opioids,
antidepressants, or neuroleptics. The risk of central nervous
system-depressant effects was even higher in patients with
psychiatric disorders, given the higher proportion of seda-
tive drugs prescribed to this population.
Thirteen percent of drug–drug interactions were phar-
macokinetic, mostly owing to drug metabolism by cyto-
chromes. Of particular interest are the interactions between
some benzodiazepines/Z-drugs and enzymatic inhibitors;
the effects of benzodiazepine drugs can be increased and,
consequently, so can their side effects (such as falls and
fractures), especially in the elderly [48]. The main sedative
drugs involved were clomethiazole, alprazolam, mirtazap-
ine, zolpidem, levomepromazine, and trazodone. Even if
specific data on clomethiazole interactions are missing, its
metabolism by cytochromes suggests a high potential for
pharmacokinetic interactions. [7]
Table 5 Sedative drug prescriptions during hospital stay and at hospital discharge
Sedative drugs prescribed During hospital stay
(n = 161)
n (%)
At hospital discharge
(n = 53)
n (%)
Medication stopped before
discharge
n (%)
Benzodiazepines 76 (47) 25 (47) 51 (67)
Z-drugs 17 (11) 6 (11) 11 (64)
Other sedative drugs (clomethiazole) 51 (32) 14 (26) 37 (73)
Antidepressants 6 (4) 3 (6) 3 (50)
Neuroleptics 5 (3) 2 (4) 3 (50)
Herbal drugs 4 (2) 2 (4) 2 (50)
Melatonin receptor agonists 2 (1) 1 (2) 1 (50)
Table 6 Prevalence of sedative
drug prescriptions during
hospital stay and at discharge
Number of sedative
drugs prescribed
During hospital stay
(n = 108)
n (%)
At hospital discharge
(n = 40)
n (%)
1 76 (70) 29 (73)
2 18 (17) 9 (22)
3 12 (11) 2 (5)
[3 2 (2) 0 (0)
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4.4 Sedative Drugs at Discharge
Of the patients prescribed new sedative drugs during their
hospital stay, 37% (n = 40) were prescribed the same
sedative at discharge. The sedative drugs newly prescribed
as PRN were less likely to be continued at discharge than
regular prescriptions. One hypothesis is that physicians
more frequently re-evaluated PRN prescriptions. These
results could be used to improve the prescription of seda-
tive drugs during hospital stays, supporting the prescription
of PRN sedative drugs whenever possible.
Clomethiazole, benzodiazepines, and Z-drugs were the
types of sedative drugs most frequently stopped at hospital
discharge in the present study. This can be explained by the
fact that these were the most prescribed drugs during
hospital stays. Moreover, two thirds of patients were pre-
scribed only one sedative drug at discharge. The prevalence
of multiple-sedative prescriptions was lower than previ-
ously reported in the literature.
Overall, hospitalization increased the number of patients
prescribed at least one sedative drug by 10% (comparison
of proportions at the beginning and end of hospital stays).
In comparison, a previous French study found a 5.4%
increase in the prescription of sedative drugs at discharge
[30]. This represents a greater potential risk of long-term
sedative use, associated with an increased risk of delirium,
falls, daily sedation, memory loss, tolerance, dependence,
or withdrawal effects [7, 8, 10]. As mentioned previously,
the elderly are most sensitive to these effects.
If sedative drugs are necessary during a hospital stay,
physicians should document any new prescription as fully
as possible, with case notes including, at the very least, the
indication for the new drug, duration of treatment, and
precautions for use. Clinical pharmacists can play a key
role in such contexts, performing thorough medication
reviews and providing recommendations on sedative use.
At discharge, physicians could use clinical pharmacists’
recommendations to inform patients about the safe use of
sedative drugs, explaining the potential side effects and
risks associated with long-term use, encouraging short-
term use, and recommending regular re-evaluations of
prescriptions by treating physicians. In this context, ward
interventions by clinical pharmacists should reinforce this
strategy by increasing the medical staff’s knowledge of
sedative drugs, proposing clear guidelines for their use,
offering alternative measures for managing insomnia dur-
ing hospitalization, and limiting the long-term use of
sedative drugs. After the completion of this study and
based on its findings, our hospital launched a Sedative
Drugs Project. The program consists of training classes for
hospital physicians and nurses, as well as a variety of
different information leaflets specially created for physi-
cians, nurses, and patients. The leaflets were created by an
interdisciplinary team and contain recommendations on the
prevention and management of sleep disorders in the hos-
pital, as well as information on the use of sedative drugs.
After a pilot phase involving several wards, the program
has now been extended to all of the hospital’s wards.
4.5 Study Strengths and Limitations
To the best of our knowledge, this study is one of only a
few to suggest that hospitals have a significant impact on
the subsequent ambulatory prescription of sedative drugs.
It provides an accurate illustration of local practices in a
Swiss regional hospital, and the number of patients inclu-
ded allowed for a thorough analysis of sedative prescrip-
tions. However, this study reflects sedative prescription
practice in only one hospital ward over a limited period of
time. Consequently, a generalization of these results should
be made with caution.
One limitation of the present study was that it aimed to
assess the prescription of sedative drugs, not their actual
administration. This implies that the actual exposure to
sedative drugs might have been overestimated by taking
into account all sedative prescriptions, including the PRN.
It therefore reflects a worst-case scenario, i.e., the case
where patients took all the sedative drugs prescribed.
However, the true administration rates of sedative drugs
could not be confirmed because the validation of drug
administration is not performed systematically in our hos-
pital’s computerized prescribing system. Moreover,
although medication reviews were performed, it was usu-
ally impossible to know the newly prescribed sedative
drug’s exact indication. This implies that patients could
have been prescribed a sedative drug for reasons other than
sleep disorders. However, whatever the indication, if one of
these drugs was used in the evening, it would probably
have an additional sedative effect. Furthermore, the true
use of a sedative drug after discharge and in the long term
could not be captured. Once again, these limitations may
have led to an overestimation of the use of sedative drugs
for sleep disorders.
5 Conclusion
This study showed that sedative medication was initiated
for 37% of patients hospitalized in an internal medicine
ward of a Swiss hospital. Moreover, at discharge, hospital
stays had increased the proportion of patients who
received a sedative drug prescription by 10%. These
prescriptions may generate long-term sedative drug use
and expose patients to DRPs (adverse effects and inter-
actions), which have been shown to be more severe in
elderly populations.
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